Four researchers from the Shafallah Medical Genetics Center (SMGC) have participated in an international human genetics meeting in San Francisco, California, USA to present the findings of their research projects in Qatar. The meeting is the 62nd annual meeting of the American Society of Human Genetics. It was held between November 6-10. It is the largest human genetics meeting and exposition in the world. It attracted about 7,000 scientific attendees and more than 200 exhibiting companies. American Society of Human Genetics members and leading scientists from around the world are selected to present their research findings at invited platform or poster sessions, during a 5 day packed programme. In addition, exhibitors show state-of-the-art medical and laboratory equipment, products, services and computer software designed to enhance human genetics research, teaching and diagnostics. The four researchers presented five posters that reflect on the research activities they had performed at SMGC in Doha. Two posters reported on gene discovery in two rare genetic conditions. One condition is found in one Qatari family and is related to mental retardation and multiple birth defects. The other condition represents a skin disease associated with a kidney defect with abnormal skin and low potassium levels in the blood of patients. A third poster reflects on the advances in bioinformatics tools that were adopted by SMGC to analyse large sets of genomic data. Two posters identify novel mutations in previously described genes and their relation to specific genetic disorders. Hassan Ali bin Ali, the chairman of the Shafallah Center, said: The researchers contribution to and participation at the American Society of Human Genetics meeting demonstrated the SMGC is now a world class genetics center that not only serves and helps the children at Shafallah, but contributes to the advancement of scientific knowledge on a global basis. The staff work very hard and it is encouraging to know that their research produces meaningful and positive outcomes.

Visit link:
Genetics Center takes part in global meet

Recommendation and review posted by Bethany Smith

LOS ANGELES, Nov. 13, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for helping determine a patient's response to cancer therapy, today announced its consolidated financial results for the third quarter ended September 30, 2012.

Total revenues for the quarter ended September 30, 2012 increased to $5.40 million, compared to $3.84 million for the quarter ended June 30, 2012 and $5.10 million for the quarter ended September 30, 2011. The Company's pharmaceutical client revenue increased by $1.37 million and the ResponseDX revenue increased by $189 thousand relative to the quarter ended June 30, 2012.

The Company's net loss for the quarter ended September 30, 2012 decreased by $1.3 million to $1.4 million compared to a net loss of $2.7 million for the quarter ended June 30, 2012 and a net loss of $1.4 million for the quarter ended September 30, 2011. This is the third consecutive quarter the Company decreased its net loss.

The Company also increased its gross margin in three consecutive quarters from approximately 25% for the fourth quarter of 2011, to approximately 32% for the quarter ended March 31, 2012 to approximately 37% for the quarter ended June 30, 2012, to approximately 49% for the quarter ended September 30, 2012. Gross margin is Net Revenue less Cost of Revenue.

Excluding cost of revenue, total operating expenses for the third quarter were $4.0 million, compared to $4.1 million for the quarter ended June 30, 2012 and $4.0 million for the same period last year.

"We are very pleased with the financial results for the quarter ended September 30, 2012, which improved again relative to the prior quarter. Since the fourth quarter of last year, we continued to realize consecutive quarter-over-quarter positive results from the many changes implemented by the Company. Gross margins have increased nearly two-fold from the fourth quarter of last year, and operating loss has continued to decrease significantly, or nearly two-fold, since last quarter and by a factor of nearly 2.8 from the fourth quarter of last year," said Thomas Bologna, the Company's Chairman & Chief Executive Officer.

Total revenues for the nine months ended September 30, 2012 were $13.2 million compared to $17.7 million for the nine months ended September 30, 2011. The decrease is largely a result of the expected decrease in pharmaceutical client revenue of $3.9 million from $8.3 million for the nine months ended September 30, 2011 to $4.4 million for the nine months ended September 30, 2012. Additionally, early in 2012, the Company made the strategic decision to focus much of its pharmaceutical resources on working with GSK as it moves its drugs, for which the Company did extensive patient testing, through the FDA approval process. The Company's ResponseDX revenue was $8.8 million for the nine months ended September 30, 2012, compared to $9.4 million for the nine months ended September 30, 2011, largely as a result of tactical changes the Company is undergoing in building and directing its sales force.

The Company's net loss for the nine months ended September 30, 2012 was $7.3 million, compared with a net loss of $1.8 million for the nine months ended September 30, 2011.

Excluding cost of revenue, total operating expenses for the nine months were $12.5 million, compared to $11.4 million for the same period last year. The increase in total operating expense of $1.1 million was due to an increase in general and administrative expenses of $0.2 million and an increase in research and development expenses of $0.9 million.

The Company's cash position increased substantially to $10.8 million at September 30, 2012 compared to $2.6 million at June 30, 2012.

Link:
Response Genetics, Inc. Announces Third Quarter Financial Results

Recommendation and review posted by Bethany Smith

NASHVILLE, Tenn.--(BUSINESS WIRE)--

Insight Genetics, Inc. today announced it has received two Small Business Innovation Research (SBIR) contracts from the National Cancer Institute (NCI) to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients. These companion diagnostic tests will be vital tools in enhancing the accuracy of cancer diagnosis and treatment, assisting physicians in determining which targeted cancer therapies are appropriate for specific patients.

Insight Genetics received a $1,495,220 Phase II contract to further develop its proprietary Insight ALK Screen that detects the complete spectrum of oncogenic anaplastic lymphoma kinase (ALK) mutations and fusions, which are associated with several types of cancer including non-small cell lung cancer (NSCLC). NCI also awarded the company a Phase I Fast Track contract of $199,576 to support research and development of a panel of companion diagnostic tests for the detection of RET, ROS1 and DEPDC1 mutations in NSCLC.

As part of its Phase II ALK contract, Insight Genetics will continue analytical and clinical validation of Insight ALK Screen, a real-time qPCR-based test being developed on a QIAGEN platform.

ALK fusions and mutations have been shown to be a contributing cause in approximately 5-10 percent of lung cancers. With knowledge of a patients ALK status, clinicians can more accurately determine if the patient will respond to ALK-inhibitor therapies, an emerging class of cancer treatments. Since only patients with ALK fusions are likely to respond to ALK inhibitors, accurate diagnostic screening is essential before prescribing ALK-targeted drugs.

Insight ALK Screen is more sensitive and specific than the other ALK detection methods currently available, said David Hout, Ph.D., Insight Genetics vice president of research and development. Our test will reduce false-negative calls of ALK status in tumors, which means more patients who may benefit from ALK inhibitor therapies will receive these targeted treatments. Since it is more easily and quickly performed than alternative tests, Insight ALK Screen also will provide actionable information to physicians and their patients in a more timely manner.

The Phase I Fast Track contract addresses a significant unmet medical need in the diagnosis and treatment of NSCLC. Collectively, RET, ROS1 and DEPDC1 mutations have been estimated to constitute up to 9 percent of all NSCLC cases, but, at present, there are no regulatory-approved, high-throughput commercial diagnostic tests that can reliably and efficiently identify these biomarkers. The Phase I contract funds nine months of work to create a panel test, with the potential to continue into Phase II funding totaling $1,499,412.

This new NCI contract allows our team to research and develop a panel of assays that detect the presence of oncogenic RET and ROS1 fusions, along with DEPDC1 expression, continued Hout. Effectively identifying these biomarkers is the only way to ensure that patients who carry them can benefit from targeted cancer therapies.

Various therapies targeting RET and ROS1, respectively, have shown good efficacy in clinical trials. Two examples are Bayers Nexavar (sorafenib) for RET and Pfizers Xalkori (crizotinib) that inhibits ROS1 as well as ALK.

These two new contracts are the third and fourth companion diagnostic awards Insight Genetics has received from NCI since 2010, said Insight Genetics President and COO Christopher Callaghan. We are delighted that NCI continues to recognize and support our companys leadership in developing diagnostics that enable the prescription of targeted cancer therapies and our commitment to improving care for cancer patients worldwide.

Link:
Insight Genetics Awarded Two National Cancer Institute Contracts to Enhance Precision in Cancer Care

Recommendation and review posted by Bethany Smith

What Are Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are non-differentiated cells with the ability to divide and produce any body cell types. The ability of stem cells to differentiate and self-regenerate impart great possibilities for disease treatment other than for restoring health, beauty and anti-aging. Clinically proven for certain illness and conditions, stem cells can now be introduced into the body to repair and replace damaged organ or tissue. For more informative articles on stem cells and stem cell therapy, please visit Stem Cell Malaysia at http:/stemcellmalaysia.com/.From:stemcells2012Views:2 1ratingsTime:06:29More inHowto Style

More:
What Are Stem Cells | Stem Cell Malaysia - Video

Recommendation and review posted by simmons

LITCHFIELDWith a name inspired by a Celtic goddess who could manifest magic for the good of others, an Elkhound mix that suffered the depths of animal abusenearly to the point of deathis benefiting from cutting-edge veterinary medicine at a practice in Bantam.

Rhiannon, whose name derives from the Stevie Nicks song about the legendary goddess, is one of two patients helping to make veterinary history in Connecticut through the states first in-clinic stem cell regenerative therapy treatments.

Such loving care stands in stark contrast to the condition Rhiannons owner, Edward Milne of Cheshire, found the 14-year-old in the first time he saw her.

I found her hanging by her neck from a tree as I was driving along a back country road in Northford, CT when she was about two years old, Mr. Milne wrote in an e-mail to the Bantam clinic, Animal Health Practice Inc.

When I confronted the owner, Mr. Milne wrote, he admitted that he had not fed her or provided her with water for some time, and when she didnt die, he hung her from the tree to finish her off. I guess it was fate that brought us together.

Another type of Rhiannon-esque fate brought the dog to a vet who is performing a ground-breaking procedure to treat severe arthritis in her elbow and back.

Rhiannon is the first dog to receive MediVet Americas non-controversial adipose regenerative stem cell therapy, according to a release sent by the company. MediVet is a global leader in veterinary science located in 29 countries. The company develops advanced cellular treatments and natural herbal remedies designed to maximize animal performance, repair, recovery and general wellness.

Were very excited to be the first veterinarians in Connecticut to offer this new technology, said Dr. Angela Erickson-Greco Monday morning.

In addition to Rhiannon, Dr. Erickson-Greco is also administering the treatment to Dakota, a Bernese Mountain Dog and Great White Pyrenees mix, who has bilateral ACL tears, which means she has torn a crucial ligament in both of her knees.

New Milford resident Cathy Morsey said Dakota had a limp in her front leg in the shoulder area at 6 months old. In January of last year, we had a wet snow and she slid on the snow and tore a cartilage in her knee, said Ms. Morsey. Continued...

Read the original:
Rhiannon, an Abused Dog, and Dakota, Get Stem Cell Therapy in Litchfield

Recommendation and review posted by simmons

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Read more:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Recommendation and review posted by simmons

Semmelweis Symposium 2012, Opening ceremony
Semmelweis University is an internationally well known biomedical university. The Semmelweis Symposium is organized annually; it is the most prestigious scientific event of the university. The main topic of the Semmelweis Symposium 2012 is bdquo;Principal Questions of Genomic Medicine: Prediction, Prevention and Personalized Treatment". Personalized medicine is paving the way for a superior health care system. Our rapidly expanding knowledge of genetics and molecular biology is creating a stronger platform for us to move ahead into a future in which care is more closely tailored than ever before. New diagnostics for identifying disorders and new therapeutic possibilities are most likely to obtain their benefits in healthcare. The anticipated arrival of the $1000 genome this year will accelerate even further the changes that have begun.From:Semmelweis EgyetemViews:23 0ratingsTime:05:33More inEducation

Follow this link:
Semmelweis Symposium 2012, Opening ceremony - Video

Recommendation and review posted by sam

AMY ~JAN 4 10.AVI
Amy was 16 yrs old when she was a passenger of a vehicle involved in a tragic crash on December 26 ,2009. She had broken her neck at the C6/7 level rendering her quadriplegic leaving her on life support fighting for her life for a month. Very much into music ,the nurses in ICU placed a radio at the head of her bed. She refused to have turned on. On the ninth day following her accident, with company in , we decided it was time to fill the room with sunlight sound. The tune she had been listening to in the car prior to the crash came on. It was one of her favorites,"Livin it up" by Ja Rule. Hooked up to life support ,suction tube in hand , Amy suddenly came to life! Her determination,inspiration motivation led her to open a Spinal Cord Injury Recovery Center in her small town Nova Scotia. Music is a healer! Thank you JaRule! Check us out (FootPrints)at http://www.sci-recovery.caFrom:Marlene BelliveauViews:13 0ratingsTime:00:26More inMusic

Go here to see the original:
AMY ~JAN 4 10.AVI - Video

Recommendation and review posted by sam

Progenitor Cell Therapy For Neurological Injury
ll4.me Progenitor Cell Therapy For Neurological Injury Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4. Neural Stem Cells-Endogenous Repair of Neurological Injury.- Chapter 5. Traumatic Brain Injury: Pathophysiology and Models.- Chapter 6. Traumatic Brain Injury: Relationship of Clinical Injury to Progenitor Cell Therapeutics.- Chapter 7. Cell-Based Therapy for Stroke.- Chapter 8. Spinal Cord Injury: Pathophysiology and Progenitor Cell Therapy.- Chapter 9. Current Status of Clinical Trials using Progenitor Cells for Neurological Injury EAN/ISBN : 9781607619659 Publisher(s): Springer, Berlin, Springer Science Business Media Discussed keywords: Neurologie, Zelltherapie Format: ePub/PDF Author(s): Cox, Charles S. Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4From:dorethacopeland98549Views:0 0ratingsTime:00:14More inPeople Blogs

Read the original here:
Progenitor Cell Therapy For Neurological Injury - Video

Recommendation and review posted by Bethany Smith

25 Multiple Sclerosis Plr Articles
ll4.me 25 Multiple Sclerosis Plr Articles 25 Multiple Sclerosis Articles - Private Label Rights Article Topics:- Treatment For Multiple Sclerosis With No Side Effects Types Of Multiple Sclerosis What Multiple Sclerotic People Should Avoid during Christmas How To Diagnose Multiple Sclerosis How To Know If It Is A Multiple Sclerosis Relapse How To Treat Multiple Sclerosis Is Cannabis Use Beneficial For Multiple Sclerosis Lifesaving Drug For Multiple Sclerosis More Information On Multiple Sclerosis Multiple Sclerosis Association Of America All About Multiple Sclerosis Causes Of Multiple Sclerosis Childbirth May Slow Multiple Sclerosis Common Human Bacteria Triggers Multiple Sclerosis Good News On Pregnancy And Multiple Sclerosis How Is Multiple Sclerosis Classified The Clinical Part Of Multiple Sclerosis The History Of Multiple Sclerosis The Kurtzke Expanded Disability Status Scale And Multiple Sclerosis Multiple Sclerosis Differential Diagnoses Not Everyone With Multiple Sclerosis Is On Treatment Pathophysiology Of Multiple Sclerosis Stem Cell Therapy Reverses Multiple Sclerosis Symptoms Of Multiple Sclerosis Teenage Obesity and Multiple Sclerosis Use the content on : Blogs/Content Pages Report Social Sites ecourses Convert to Audios ebook Bundle and Sell as Products Personal Education, Tips Training Whatever you might imagine... RIGHTS:- [YES] Can Be Sold [YES] Can Be Packaged [YES] Can Be Offered As a Bonus [YES] Can Be Added As Web Content [YES] Can Be Used For Product ...From:rebeccahenson9854Views:0 0ratingsTime:00:14More inPeople Blogs

See the original post:
25 Multiple Sclerosis Plr Articles - Video

Recommendation and review posted by Bethany Smith

Charles - USA Stem Cells Testimonial
If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.From:USAStemcellsViews:4 0ratingsTime:10:04More inScience Technology

Read the rest here:
Charles - USA Stem Cells Testimonial - Video

Recommendation and review posted by Bethany Smith

Thelma before Stem Cell Therapy
From:krazykp12Views:13 0ratingsTime:01:33More inPeople Blogs

See more here:
Thelma before Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Ann Charland #39;s live cell therapy 2012
Ann Charland talking about her experience 2012 with live cell therapy by Dr. med. R. Janson-Müller (Hotel Prinzregent, Edenkoben, Germany)From:FrischzellenViews:1 0ratingsTime:00:49More inEducation

Excerpt from:
Ann Charland's live cell therapy 2012 - Video

Recommendation and review posted by Bethany Smith

SHIMMIAN MANILA - Celebs share good effects of stem cell therapy
From:myrenovatiosolutionsViews:1 0ratingsTime:01:30More inEntertainment

Read this article:
SHIMMIAN MANILA - Celebs share good effects of stem cell therapy - Video

Recommendation and review posted by Bethany Smith

VimedCell - The long success story of Vimed Living Cells
VimedCell, over 20 years of experience in cell therapy to the principles of Prof. Dr. Niehans. More than 5 million people have been treated successfully with living cells. VimedCell, add quality to live by staying healthy and youthful. Offering you personalised biological ageing treatment to achieve new health and vitality. Experts behind research and development with stringent quality control. VimedCell, you will be in best hands with us. http://www.vimedcell.com #1058; #1077; #1088; #1072; #1087; #1080; #1103; #1078; #1080; #1074; #1099; #1084; #1080; #1082; #1083; #1077; #1090; #1082; #1072; #1084; #1080; VimedCell -- #1101; #1090; #1086; #1094; #1077; #1083; #1086; #1089; #1090; #1085; #1099; #1081; #1080; #1085; #1089; #1090; #1088; #1091; #1084; #1077; #1085; #1090;, #1076; #1077; #1081; #1089; #1090; #1074; #1080; #1077; #1082; #1086; #1090; #1086; #1088; #1086; #1075; #1086; #1079; #1072; #1082; #1083; #1102; #1095; #1072; #1077; #1090; #1089; #1103; #1074; #1088; #1077; #1075; #1077; #1085; #1077; #1088; #1072; #1094; #1080; #1080; #1086; #1082; #1083; #1077; #1090; #1086; #1082; #1089; #1086; #1073; #1089; #1090; #1074; #1077; #1085; #1085; #1086; #1075; #1086; #1086; #1088; #1075; #1072; #1085; #1080; #1079; #1084; #1072; #1080; #1077; #1075; #1086; #1074; #1086; #1089; #1089; #1090; #1072; #1085; #1086; #1074; #1083; #1077; #1085; #1080; #1080;. http://www.vimedcell.com #1610; #1593; #1605; #1604; #1575; #1604; #1582; #1604; #1610; #1577; #1575; #1604; #1581; #1610; #1577; VimedCell #1575; #1604; #1593; #1604; #1575; #1580; #1603; #1571; #1583; #1575; #1577; #1604; #1578; #1606; #1588; #1610; #1591; #1603; #1604; #1610; #1582; #1604; #1575; #1610; #1575; #1575; #1604; #1580; #1587; #1605; #1606; #1601; #1587; #1607; #1608; #1578; #1580; #1583; #1610; #1583; #1575; #1604; #1603; #1575; #1574; #1606; #1575; #1604; #1581; #1610; #1576; #1571; #1603; #1605; #1604; #1607;. #1608; #1607; #1584; #1575; . #1610; #1593; #1606; #1610; #1571; #1606; #1571; #1587; #1604; #1608; #1576; #1575; #1604; #1593; #1604; #1575; #1580; #1610; #1583; #1593; #1605; #1602; #1583; #1585; #1577; #1575; #1604; #1588; #1582; #1589; #1593; #1604; #1609; #1575; #1604; #1578; #1580; #1583; #1583; #1608; #1610; #1593; #1586; #1586; #1581; #1610; #1608; #1610; #1578; #1607; #1575; #1575; #1604; #1582; #1575; #1589; #1577;. VimedCell #27963; #32454; #32990; #30103; #27861; #21487; #20316; #20026; #20351; #26426; #20307; #33258; #36523; #32454; #32990; #37325; #33719; #29983; #21629; #21147; #24182; #20351; #25972; #20010; #26426; #20307; #20877; #29983; #30340; #25972; #20307; #24037; #20855; #32780; #20351; #29992; #12290; #36825; #24847; #21619; #30528; #35813; #30103; #27861; #25903; #25345; #20154; #33258; #24049; #30340; #20877; #29983; #33021; #21147; #24182; #22686; #24378; #26426; #20307; #27963; #21147; #12290;www.vimedcell.com A VimedCell Living Cell Therapy é empregada como uma ferramenta holística para revitalizar as próprias células do corpo e regenerar o organismo inteiro. http://www.vimedcell.com La thérapie VimedCell cellule vivante est utilisée comme un outil complet pour revitaliser les propres cellules de l #39;organisme et régénérer l #39;organisme tout entier. http://www.vimedcell.comFrom:vimedcellViews:1 0ratingsTime:02:58More inPeople Blogs

See the rest here:
VimedCell - The long success story of Vimed Living Cells - Video

Recommendation and review posted by Bethany Smith

By Philip C. Tubeza Philippine Daily Inquirer

The Department of Health (DOH) on Saturday warned those contemplating stem cell therapy against using stem cells from aborted babies and human embryos.

The DOH issued the statement as it reviewed the legal and technical specifications of stem cell therapy to come up with a regulatory framework.

The Philippine government will not allow the use of aborted fetuses or human embryos (as sources of stem cells). There is a need to ensure that the biological raw materials are documented and validated and follow infection-free procedures, the health department said.

There is also a need to know if the materials to be injected came from animal or human tissues, it added.

The DOH said the other fundamental areas of the regulatory framework would include the monitoring of the marketing claims by medical centers that offer stem cell therapy so that the claims stick within the boundaries of science as objectively as possible.

Credentials and procedures

The credentials of the scientists involved should also match the training, education and skills required for these procedures while good laboratory procedures should be observed in the preparation of the tissue and cells, the DOH said.

The centers to be regulated or accredited will have to show both positive and negative outcomes for a better handle of the predictors of success or failure from this intervention, it said.

The health department said there was a need for a regulatory framework because there were many steps in the preparation of stem cell therapies and the government had been receiving many queries about it.

Read the rest here:
DOH warns against use of stem cells from aborted babies

Recommendation and review posted by Bethany Smith

Washington, Nov. 9 (ANI)

Mutations in a single gene - that causes intellectual disability and increases the risk of developing autism spectrum disorder - severely disrupts the organization of developing brain circuits during early childhood, a new study has revealed.

This study by scientists from the Florida campus of The Scripps Research Institute helps explain how genetic mutations can cause profound cognitive and behavioural problems.

"In this study, we did something no one else had done before," Gavin Rumbaugh, a TSRI associate professor who led the new research, said.

"Using an animal model, we looked at a mutation known to cause intellectual disability and showed for the first time a causative link between abnormal synapse maturation during brain development and life-long cognitive disruptions commonly seen in adults with a neurodevelopmental disorder," he said.

The study focused on a critical synaptic protein known as SynGAP1.

Mutations in the gene that encodes this protein cause disabilities in an estimated one million people worldwide, according to the paper.

"You might think this accelerated development of brain circuits would make you smarter," Rumbaugh said.

"But the increased excitability actually disorganizes brain development. We think that early maturation of these excitatory synapses disrupts the timing of later developmental milestones. It rains down chaos on this complex process, preventing normal intellectual and behavioural development," he said.

The study has been published in the journal Cell.

View post:
Gene mutation behind brain defects identified

Recommendation and review posted by Bethany Smith

THURSDAY, Nov. 8 (HealthDay News) -- Specific DNA variations explain more than 10 percent of the inherited genetic risk for developing heart disease, a new study suggests.

Researchers discovered 20 previously unidentified genetic variations in more than 63,000 people with coronary artery disease, which causes more deaths worldwide than any other disease.

These variations were uncommon in a control group of more than 130,000 people without heart disease.

The newly identified mutations bring to 47 the total number of genetic variations that have so far been linked to an increased risk for developing heart disease, according to study co-leader Panos Deloukas, head of the Genetics of Complex Traits in Humans research group at the Wellcome Trust Sanger Institute, in Cambridge, England.

One previous study estimated that 30 percent to 60 percent of heart disease cases might be attributable to genetic risk factors. This new study increases the number of genes likely involved in coronary artery disease.

The study was to be presented Thursday at the American Society of Human Genetics annual meeting in San Francisco.

"We no longer assume that coronary heart disease is triggered by just a handful of genes, each with a strong effect on a person's risk for the disease," Deloukas said in a society news release. "Our research supports the current assumption that heart disease risk is determined by a large group of genes, each with a modest effect on risk."

Deloukas said pinpointing the genetic variations involved in coronary artery disease may lead to improved treatments, and noted that many of the newly identified variations are in genes involved in the body's metabolism of fats as well as in inflammation.

The findings highlight the roles of high cholesterol levels and inflammation in coronary artery disease, Deloukas said.

Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

Here is the original post:
More Gene Variants Linked to Heart Trouble

Recommendation and review posted by Bethany Smith

Washington, Nov. 9 (ANI): Mutations in a single gene - that causes intellectual disability and increases the risk of developing autism spectrum disorder - severely disrupts the organization of developing brain circuits during early childhood, a new study has revealed.

This study by scientists from the Florida campus of The Scripps Research Institute helps explain how genetic mutations can cause profound cognitive and behavioural problems.

"In this study, we did something no one else had done before," Gavin Rumbaugh, a TSRI associate professor who led the new research, said.

"Using an animal model, we looked at a mutation known to cause intellectual disability and showed for the first time a causative link between abnormal synapse maturation during brain development and life-long cognitive disruptions commonly seen in adults with a neurodevelopmental disorder," he said.

The study focused on a critical synaptic protein known as SynGAP1.

Mutations in the gene that encodes this protein cause disabilities in an estimated one million people worldwide, according to the paper.

"You might think this accelerated development of brain circuits would make you smarter," Rumbaugh said.

"But the increased excitability actually disorganizes brain development. We think that early maturation of these excitatory synapses disrupts the timing of later developmental milestones. It rains down chaos on this complex process, preventing normal intellectual and behavioural development," he said.

The study has been published in the journal Cell. (ANI)

Visit link:
Gene mutation that cause brain defects identified

Recommendation and review posted by Bethany Smith

DNA cloning
For more information, log on to- shomusbiology.weebly.com Download the study materials here- shomusbiology.weebly.com This video tutorial describes the process of DNA cloning and its importance in genetic engineering.From:Suman BhattacharjeeViews:0 0ratingsTime:19:56More inEducation

View post:
DNA cloning - Video

Recommendation and review posted by Bethany Smith

Fundamentals Of Weed Science - Robert L. Zimdahl
ll4.me Fundamentals Of Weed Science - Robert L. Zimdahl This book addresses herbicides and their use as an important aspect of modern weed management,and strives to place them in an ecological framework. Many weed scientists believe agriculture is a continuing struggle with weeds - without good weed control, good and profitable agriculture is impossible. Each agricultural discipline sees itself as central to agriculture #39;s success and continued progress, and weed science is no exception. While notdenying the importance of weed management to successful agriculture, this book places it in alarger ecological context. The roles of culture, economics, and politics in weed management are also discussed, enabeling scientists and students to understand the larger effects on society.NEW TO THIS EDITION: * Information on New herbicides included, along with the old herbicides that are important for understanding the history * New section on weed resistance to herbicides and genetic engineering * New information on invasive plants * Expanded chapters on Biological Control, Pesticide Legislation and Regulation, Weed Management Systems, and moreAuthor: Zimdahl, Robert L. Publisher: Academic Press Illustration: N Language: ENG Title: Fundamentals of Weed Science Pages: 00000 (Encrypted PDF) On Sale: 2007-09-06 SKU-13/ISBN: 9780123725189 Category: Science : Life Sciences - Botany Category: Science : Environmental Science Category: Technology Engineering : Agriculture - General This book ...From:leslietessier9854Views:0 0ratingsTime:00:14More inPeople Blogs

More:
Fundamentals Of Weed Science - Robert L. Zimdahl - Video

Recommendation and review posted by Bethany Smith

Port Townsend Food Coop: "I want to know what is in my food"
In front of the Port Townsend Food Coop, I conducted a series of customer interview regarding GMOs. I-522 is an initiative to the Washington State legislature to establish mandatory labeling of foods produced through genetic engineering. As recommended by the Secretary of State, the LabelitWA group needs to turn in at least 320000 signatures to ensure they have 241153 valid signatures by December 31, 2012 in order to get on the November 2013 ballot. I-522, "The People #39;s Right to Know Genetically Engineered Food Act," is simple. The initiative would require food sold in retail outlets to be labeled if the ingredients are produced through genetic engineering. An estimated 70 percent of non-organic processed foods contain some #9472; or several #9472; genetically engineered ingredients. http://www.labelitwa.org http California 2012 Prop 37 Playlist http://www.youtube.com Sponsor RAAW Foods (Non-GMO Project Verified) http://www.raawfoods.comFrom:digitalreporterViews:0 0ratingsTime:03:45More inTravel Events

Follow this link:
Port Townsend Food Coop: "I want to know what is in my food" - Video

Recommendation and review posted by Bethany Smith

editta braun company: planet LUVOS (clip, 4:33)
performed by: Scaron;pela Vodeb, Dorota Karolina #321; #281;cka, Andrea Maria Handler, Marcella Mancini, Katja Bablick, Sandra Hofstötter, Martyna Lorenc dramaturgy: Gerda Poschmann-Reichenau, composition: Thierry Zaboitzeff, lightdesign: Peter Thalhamer, choreographic assistance: Barbara Motschiunik, Juan Dante Murillo Bobadilla, choreograpy: Editta Braun What remains is greater than man "planet LUVOS", the editta braun company #39;s fascinating dance premiere at the Bruckner Festival - Upper Austrian News, September 29, 2012 The Salzburg choreographer Editta Braun leads us through a blue underwater world back to the origins of life. In her new piece "planet LUVOS", she completes the round dance of surreal body worlds, which began with "Lufus" (1985) and continued with "Lufus, vol. 2", about the dangers of genetic engineering. The viewer sinks into a blue, bubbling waterworld. The only sign that humans exist is the distant sound of a steamship whistle, somewhere far away. And a woman who suddenly finds herself in a kingdom full of strange, but peaceful beings. Seven dancers (Katja Bablick, Andrea Maria Handler, Sandra Hofstötter, Dorota Karolina Lecka, Martyna Lorenc, Marcella Mancini and Spela Vodeb) constitute this symbiotic, sensitive collective. Their legs wave in the air like anemone arms, each movement reacting as fast as lightning to the other . Their bodies lose their humanness and become entities. Naked torsi move like alien beings across the stage. These are fascinating images, a ...From:edittabrauncompanyViews:1 0ratingsTime:04:31More inEducation

Link:
editta braun company: planet LUVOS (clip, 4:33) - Video

Recommendation and review posted by Bethany Smith

Port Townsend Food Coop: GMO I-522 Series - Gunther Dohse
In front of the Port Townsend Food Coop, Gunther Dohse talks about signing the I-522 petition, being a coop member and healthy living. I-522 is an initiative to the Washington State legislature to establish mandatory labeling of foods produced through genetic engineering. As recommended by the Secretary of State, the LabelitWA group needs to turn in at least 320000 signatures to ensure they have 241153 valid signatures by December 31, 2012 in order to get on the November 2013 ballot. I-522, "The People #39;s Right to Know Genetically Engineered Food Act," is simple. The initiative would require food sold in retail outlets to be labeled if the ingredients are produced through genetic engineering. An estimated 70 percent of non-organic processed foods contain some #9472; or several #9472; genetically engineered ingredients. http://www.labelitwa.org http California 2012 Prop 37 Playlist http://www.youtube.com Sponsor RAAW Foods (Non-GMO Project Verified) http://www.raawfoods.comFrom:digitalreporterViews:0 0ratingsTime:02:47More inNonprofits Activism

See the rest here:
Port Townsend Food Coop: GMO I-522 Series - Gunther Dohse - Video

Recommendation and review posted by Bethany Smith

The luminescent angel fish were created by Taiwanese bio-technologists Photos show the fish - the first of their kind - as they are unveiled in Taipei

By Sam Webb

PUBLISHED: 22:13 EST, 7 November 2012 | UPDATED: 22:15 EST, 7 November 2012

These incredible images show the worlds genetically-engineered pink fluorescent fish as they are unveiled at an exhibition in Taipei.

The fish, latin name Archocentrus nigrofasciatus var, glow brightly without the aid of ultraviolet lamps commonly placed in fish tanks.

They were created by a joint project between Taiwans Academia Sinica, National Taiwan Ocean University and Jy Lin, a private biotechnology company.

Scientific marvel: The genetically-engineered angelfish, the first of their type in the world, glow in a tank during a news conference before the 2012 Taiwan International Aquarium Expo in Taipei

They were unveiled at a news conference for the 2012 Taiwan International Aquarium Expo, to be held at Taipei World Trade Center Nangang Exhibition Hall from tomorrow.

When light is produced by an organism using a chemical reaction it is called bioluminescence and it most commonly occurs in sea creatures.

Originally posted here:
Pink Angel Delight: Genetically-engineered angelfish that glow in the dark go on display in Taiwan

Recommendation and review posted by Bethany Smith